XML 153 R46.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
USD ($)
numberOfSegments
Mar. 31, 2024
USD ($)
Segment Reporting [Abstract]    
Number of reportable segments | numberOfSegments 1  
Segment Reporting Information [Line Items]    
Revenues $ 1,764 $ 1,532
General and administrative 5,832 5,312
Segment net loss (24,526) (17,875)
Adjustments and reconciling items 0 0
Reportable Segment    
Segment Reporting Information [Line Items]    
Revenues 1,764 1,532
Research and development employee expense, lab supplies and overhead 4,436 7,100
Imdusiran IM-PROVE I, II & III clinical trials expense 2,384 5,389
AB-101-001 Phase 1a/1b clinical trial expense 1,899 2,810
Other early research and development programs expense 240 104
General and administrative 5,832 5,312
Restructuring costs 12,373 0
Other segment expense 323 237
Interest income 1,197 1,545
Segment net loss $ (24,526) $ (17,875)
Consolidated net loss (24,526) (17,875)